Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study

Abstract: Background: Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice.